Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026

Rhea-AI Summary

Apogee Therapeutics (Nasdaq: APGE) will report interim results from its Phase 1b trial of APG777 in patients with mild-to-moderate asthma on Tuesday, January 6, 2026.

The company will host a conference call and live webcast on January 6, 2026 at 8:00 a.m. ET to discuss the interim data. The live webcast can be accessed via the company’s investor website at https://investors.apogeetherapeutics.com/news-events/events and a replay will be available after the call.

Key Figures

Interim results date January 6, 2026 Phase 1b APG777 trial in mild-to-moderate asthma

Webcast time 8:00 a.m. ET Conference call to discuss APG777 Phase 1b interim results

Market Reality Check

$78.06 Last Close

Volume Volume 901,455 vs 20-day average 987,019 (relative volume 0.91) ahead of the interim data call. normal

Technical Shares at $75.78 trading above the 200-day MA of $46.34 and 6.43% below the $80.99 52-week high.

Peers on Argus

Peers show mixed, low-magnitude moves (e.g., ARQT +0.21%, AGIO -0.26%, TVTX +1.05%), suggesting today’s setup for APGE’s APG777 interim data call is stock-specific rather than part of a broad biotech move.

Common Catalyst Select peers like AGIO also issued event-focused announcements (conference participation), but without a clear sector-wide catalyst.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 10	Earnings and pipeline	Positive	+3.8%	Q3 2025 results plus cash runway and four 2026 clinical readouts.
Nov 10	Clinical trial update	Positive	+3.8%	Positive interim Phase 1 data for APG333 in healthy volunteers.
Nov 03	Conference participation	Neutral	-4.0%	Announcement of participation in multiple investor conferences.
Oct 10	Equity offering	Negative	+2.9%	Closing of $345M underwritten public offering with warrants.
Oct 08	Equity offering pricing	Negative	+18.9%	Pricing of $300M public offering of stock and pre-funded warrants.

Pattern Detected

APGE has often traded positively on clinical and financing news, even when events could be viewed as dilutive or neutral, indicating a pattern of constructive reactions to growth and pipeline updates.

Recent Company History

Over the last few months, Apogee reported Q3 2025 results with four anticipated 2026 clinical readouts and a strong cash position of $913M pro forma, which coincided with a 3.77% gain. Positive interim Phase 1 data for APG333 in healthy volunteers on Nov 10, 2025 also matched that move. The company raised roughly $300M–$345M via public offerings in October 2025, which saw positive price reactions, while a neutral conference-participation update in November drew a modest decline. Today’s APG777 interim-results call fits into this cadence of frequent clinical updates.

Market Pulse Summary

This announcement sets expectations for interim Phase 1b results of APG777 in mild-to-moderate asthma, with a webcast on January 6, 2026 at 8:00 a.m. ET. It follows a series of clinical and financing milestones, including positive APG333 data and substantial capital raises, that left shares trading well above the $46.34 200-day MA. Investors may focus on how the asthma data fit into Apogee’s broader I&I strategy and upcoming 2026 readouts.

Key Terms

phase 1b medical

"report interim results from its Phase 1b trial of APG777"

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

biologics medical

"advancing optimized, novel biologics with potential for best-in-class profiles"

Biologics are medicines made from living cells or their components rather than from simple chemical recipes, more like a handcrafted product than a mass-produced pill. They matter to investors because they often command higher prices and longer patent protection but also carry greater manufacturing, regulatory and supply risks—so a successful biologic can boost a company’s revenue significantly, while setbacks can quickly affect its stock.

immunology medical

"in the largest inflammatory and immunology (I&I) markets"

Immunology is the study of the body’s defense system—how cells and molecules detect and fight infections, cancers and other threats, much like a building’s security system that spots intruders and sounds alarms. For investors, advances or setbacks in immunology matter because they drive the development, approval and market potential of vaccines, cancer therapies and diagnostics, affecting revenue prospects, regulatory risk and company valuations.

AI-generated analysis. Not financial advice.

Webcast to be held Tuesday, January 6th at 8:00 a.m. ET

SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report interim results from its Phase 1b trial of APG777 in patients with mild-to-moderate asthma on Tuesday, January 6, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.

Webcast Details
Apogee Therapeutics’ live webcast of the APG777 Phase 1b asthma interim results will begin on Tuesday, January 6^th at 8:00 a.m. ET. The live webcast can be accessed via this link or the Investors section on the Company’s website at https://investors.apogeetherapeutics.com/news-events/events. A replay of the webcast will be available following the call.

About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest I&I markets, including for the treatment of AD, asthma, EoE, COPD and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://apogeetherapeutics.com.

Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com

Media Contact:
Dan Budwick
1AB
dan@1abmedia.com

FAQ

When will Apogee Therapeutics (APGE) report interim APG777 Phase 1b results?

Apogee will report interim Phase 1b results on Tuesday, January 6, 2026 and discuss them on a call at 8:00 a.m. ET.

How can investors access the APGE conference call and webcast on January 6, 2026?

The live webcast is available via the company’s investor events page at https://investors.apogeetherapeutics.com/news-events/events.

What clinical study is Apogee discussing on the January 6, 2026 call for APG777?

The call will cover interim results from the Phase 1b trial of APG777 in patients with mild-to-moderate asthma.

Will a replay of the APGE January 6, 2026 webcast be available?

Yes. A replay of the webcast will be available on the company’s investor website after the call.

What time is the Apogee (APGE) webcast on January 6, 2026 and what will be discussed?

The webcast begins at 8:00 a.m. ET on January 6, 2026 and will discuss interim APG777 Phase 1b trial results.